Personal CFO Solutions LLC Raises Stock Holdings in GSK plc (NYSE:GSK)

Personal CFO Solutions LLC lifted its holdings in shares of GSK plc (NYSE:GSK) by 5.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,724 shares of the pharmaceutical company’s stock after acquiring an additional 626 shares during the quarter. Personal CFO Solutions LLC’s holdings in GSK were worth $397,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Sunbelt Securities Inc. increased its position in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co increased its position in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 500 shares during the last quarter. Crews Bank & Trust purchased a new stake in shares of GSK during the fourth quarter valued at approximately $26,000. ST Germain D J Co. Inc. increased its position in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Finally, Sierra Ocean LLC bought a new position in GSK during the fourth quarter valued at $32,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

GSK stock opened at $40.08 on Monday. GSK plc has a one year low of $31.72 and a one year high of $45.92. The business has a fifty day moving average price of $35.47 and a 200-day moving average price of $37.14. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market capitalization of $83.07 billion, a P/E ratio of 25.21, a PEG ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities research analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 3.92%. GSK’s dividend payout ratio (DPR) is currently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.